Dermatol. praxi. 2021;15(2):105-107 | DOI: 10.36290/der.2021.021

Rituximab

prof. MUDr. Hana Jedličková, Ph.D.
I. dermatovenerologická klinika FN u sv. Anny v Brně

Rituximab is a monoclonal antibody to the CD20 antigen of B lymphocytes, primarily used in the therapy of haemato-oncologic diseases. Its effect is depletion of B lymphocytes and so it is also used in the therapy of autoimmune diseases, including bullous dermatoses, especially pemphigus. Its early administration in pemphigus has been shown to significantly shorten the time to remission and reduce the total dose of corticosteroids and immunosuppressants administered.

Keywords: rituximab, pemphigus, therapy.

Published: September 2, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jedličková H. Rituximab. Dermatol. praxi. 2021;15(2):105-107. doi: 10.36290/der.2021.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zadražil J, Horák P, Karásek D, a kol. Rituximab in Moderní farmakoterapie autoimunitních chorob. 2. aktualizované a doplněné vydání. Maxdorf. 2019, 488.
    2. Didona D, Maglie R, Rüdiger Eming R, Hertl M. Pemphigus: Current and Future Therapeutic Strategies Front. Immunol., 25 June 2019. https://doi.org/10.3389/fimmu.2019.01418 Go to original source... Go to PubMed...
    3. Souhrn údajů o přípravku Mab Thera 100 mg. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_cs.pdf
    4. Boyer-Suavet S, Andreani M, Lateb M, a kol. Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab Front. Immunol., 13 January 2020. Dostupné z: https://doi.org/10.3389/fimmu.2019.03069 Go to original source... Go to PubMed...
    5. Murrell D, et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts J Am Acad Dermatol. 2020; 82(3): 575-585. Go to original source... Go to PubMed...
    6. Russo I, Miotto S, Saponeri A, Alaibac M. Ultra-low dose rituximab for refractory pemphigus vulgaris: a pilot study. Expert Opin Biol Ther. 2020; 20(6): 673-678. Go to original source... Go to PubMed...
    7. Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet Lond Engl 2017; 389: 2031-2040 Go to original source... Go to PubMed...
    8. Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review. Int Immunopharmacol 2018; 54: 131-138. Go to original source... Go to PubMed...
    9. Joly P, Horvath B, Patsatsi A, a kol. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology (EADV). JEADV. 2020; 34: 1900-1913. Go to original source... Go to PubMed...
    10. Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horváth B. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases. Front Immunol. 2018; 9: 248. doi: 10.3389/fimmu.2018.00248. PMID: 29520266. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.